- Tumor mutation burden is a predictive biomarker for survival to patients with ovarian carcinomaLiu, N.; Huang, C.; He, J.; Lu, J.; Wang, S.Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), ELECTR NETWORK, 2022-09-09 To 2022-09-13.
- Concordance between Immunohistochemistry for DNA Mismatch Repair Proteins and Next Generation Sequencing for the Identification of Microsatellite Instability in Endometrial CancerPaula, Arnaud Da Cruz; DeLair, Deborah; Fix, Daniel; Soslow, Robert; Park, Kay; Chiang, Sarah; Reis-Filho, Jorge; Zehir, Ahmet; Mandelker, Diana; Murali, Rajmohan; Makker, Vicky; Cadoo, Karen; Mueller, Jennifer; Leitao, Mario; Abu-Rustum, Nadeem; Aghajanian, Carol; Weigelt, Britta109th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP), Los Angeles, CA, 2020-02-29 To 2020-03-05.
- Mutations in LRRK2 are Associated with Improved Outcomes and Frequent DNA Polymerase Exonuclease Defects in Endometrial CancerClinton, Lani; Sanders, Laurie H.; Castellar, Edgardo Parrilla109th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP), Los Angeles, CA, 2020-02-29 To 2020-03-05.
会议论文
Tumour mutation burden is a dispensable test in endometrial carcinoma patients whose molecular classification is known
10阅读
